Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials

BACKGROUND: Irritable bowel syndrome with diarrhea (IBS-D) is a prevalent gastrointestinal (GI) disorder with a varied presentation, often overlapping with other GI and non-GI disorders. Eluxadoline is a locally active mixed µ- and κ-opioid receptor agonist and δ-opioid receptor antagonist approved...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Therap Adv Gastroenterol
Autors principals: Lacy, Brian E., Harris, Lucinda A., Chang, Lin, Lucak, Susan, Gutman, Catherine, Dove, Leonard S., Covington, Paul S., Lembo, Anthony
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6466471/
https://ncbi.nlm.nih.gov/pubmed/31019552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284819841290
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars